Louisiana's share of EpiPen overbilling settlement is $6.9M
BATON ROUGE - Louisiana is getting $6.9 million from EpiPen maker Mylan as part of a national settlement.
Attorney General Jeff Landry announced the state's share of the $465 million federal agreement completed in August that settled allegations it overbilled Medicaid programs for its emergency allergy injectors for nearly a decade.
Landry called it Medicaid fraud. In a statement, he said people and companies that "deceive the hard-working taxpayers of Louisiana should be held accountable for their actions."
It's the second settlement with the U.S. Department of Justice that Mylan has made since 2009 for allegedly overcharging the government. The latest case involves Mylan paying Medicaid too-low rebates for the devices by classifying its brand-name product as a generic, which requires lower rebates.
Desktop NewsClick to open Continuous News in a sidebar that updates in real-time.
LSU begins digitizing century-old editions of longtime campus newspaper
Hundreds of volunteers pick up litter around the capital city
New entertainment venue set to open at Mall of Louisiana in 2019
Cheeky Capitol parking lot security system strikes again
Denham Springs adds second resource officer to watch its schools